These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17478477)

  • 1. Screening for positive allosteric modulators: assessment of modulator concentration-response curves as a screening paradigm.
    Langmead CJ
    J Biomol Screen; 2007 Aug; 12(5):668-76. PubMed ID: 17478477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of allosterism in functional assays.
    Ehlert FJ
    J Pharmacol Exp Ther; 2005 Nov; 315(2):740-54. PubMed ID: 16046613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
    Keov P; Sexton PM; Christopoulos A
    Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
    Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.
    O'Brien JA; Lemaire W; Chen TB; Chang RS; Jacobson MA; Ha SN; Lindsley CW; Schaffhauser HJ; Sur C; Pettibone DJ; Conn PJ; Williams DL
    Mol Pharmacol; 2003 Sep; 64(3):731-40. PubMed ID: 12920211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining allosteric modulator mechanism of action: integration of radioligand binding and functional assay data.
    Langmead CJ
    Methods Mol Biol; 2011; 746():195-209. PubMed ID: 21607858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.
    Johnson MP; Nisenbaum ES; Large TH; Emkey R; Baez M; Kingston AE
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):881-7. PubMed ID: 15494040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for positive allosteric modulators of biological targets.
    Groebe DR
    Drug Discov Today; 2006 Jul; 11(13-14):632-9. PubMed ID: 16793532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the potency and molecular mechanism of action of insurmountable antagonists.
    Kenakin T; Jenkinson S; Watson C
    J Pharmacol Exp Ther; 2006 Nov; 319(2):710-23. PubMed ID: 16857731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
    Avlani V; May LT; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.
    Ehlert FJ
    Mol Pharmacol; 1988 Feb; 33(2):187-94. PubMed ID: 2828914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand detection in the allosteric world.
    Kenakin TP
    J Biomol Screen; 2010 Feb; 15(2):119-30. PubMed ID: 20086210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors.
    Lanzafame A; Christopoulos A
    J Pharmacol Exp Ther; 2004 Mar; 308(3):830-7. PubMed ID: 14617684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding.
    Figler H; Olsson RA; Linden J
    Mol Pharmacol; 2003 Dec; 64(6):1557-64. PubMed ID: 14645687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
    Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
    Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of asymmetry of concentration-response curves on the results obtained by the receptorial responsiveness method (RRM): an in silico study.
    Grenczer M; Zsuga J; Majoros L; Pinter A; Kemeny-Beke A; Juhasz B; Tosaki A; Gesztelyi R
    Can J Physiol Pharmacol; 2010 Nov; 88(11):1074-83. PubMed ID: 21076495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.
    Chen Y; Goudet C; Pin JP; Conn PJ
    Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G-protein-coupled receptor allosterism: the promise and the problem(s).
    Christopoulos A; May LT; Avlani VA; Sexton PM
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):873-7. PubMed ID: 15494038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of models for analysis of radioligand binding data.
    Abramson SN; McGonigle P; Molinoff PB
    Mol Pharmacol; 1987 Jan; 31(1):103-11. PubMed ID: 3027522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
    Burford NT; Watson J; Bertekap R; Alt A
    Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.